Ehab Ghazy

Dr. Ehab Ghazy is a researcher at the Department of Medicinal Chemistry, Institute of Pharmacy, Faculty of Natural Sciences I - Biosciences, Martin Luther University Halle-Wittenberg. His work centers on the development of selective histone deacetylase (HDAC) inhibitors, particularly targeting HDAC8, through an integrated approach combining computational modeling, organic synthesis, and biological evaluation.

His research spans oncology and parasitology, with significant contributions to the development of novel therapeutics for neuroblastoma, schistosomiasis, leishmaniasis, and cestode infections. He employs structure-based drug design, molecular dynamics simulations, QSAR modeling, and dual-target inhibition strategies to optimize drug candidates for potency and selectivity.

The analysis of his recent publications reveals a strong focus on epigenetic drug discovery, particularly in repurposing or designing HDAC inhibitors for both cancer and neglected tropical diseases. His work often involves the design of dual-target inhibitors and PROTACs, reflecting a modern, sophisticated approach to medicinal chemistry.

• 2023: Explored oncogenic feedback loops in neuroblastoma.
• 2022: Developed PROTACs targeting HDAC8 for neuroblastoma and HDAC inhibitors for schistosomiasis.
• 2021: Advanced smHDAC8 inhibitors with SAR, cocrystallization, and computational modeling, while also exploring HDAC inhibitors for cestodiasis.
• 2020: Designed dual HDAC6/8 and BRPF1 inhibitors, identified Sirt5 inhibitors, and evaluated HDAC inhibitors against Leishmania.
• 2019–2016: Pioneered tools for HDAC activity monitoring and developed dual epigenetic inhibitors.

No scientific awards are mentioned in the provided text.

Dr. Ghazy has collaborated extensively with researchers such as W. Sippl, M. Jung, D. Robaa, and others. While no direct mention of student supervision or grants is made, his involvement in multiple high-impact publications suggests active participation in research projects and collaborative networks. He has presented his work at conferences including the German Peptide Symposium and Drug Innovation in Academia, indicating engagement with the broader scientific community.

He is part of the Medicinal Chemistry research group, contributing to projects involving epigenetic modulators, antiparasitic agents, and cancer therapeutics. The group utilizes advanced techniques such as X-ray crystallography, molecular docking, and in vitro testing to drive drug discovery.